• Thumbnail for Abciximab
    Abciximab, a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro,...
    9 KB (671 words) - 19:42, 20 December 2023
  • a class of antiplatelet agents. Several GpIIb/IIIa inhibitors exist: abciximab (abcixifiban) (ReoPro) eptifibatide (Integrilin) tirofiban (Aggrastat)...
    2 KB (175 words) - 18:45, 17 January 2024
  • fibrinogen. The gpIIb/IIIa receptor is a target of several drugs including abciximab, eptifibatide, and tirofiban. Once platelets are activated, granules secrete...
    5 KB (500 words) - 06:24, 21 December 2023
  • (Persantine) Glycoprotein IIB/IIIA inhibitors (intravenous use only) Abciximab (ReoPro) Eptifibatide (Integrilin) Tirofiban (Aggrastat) Irreversible...
    18 KB (1,752 words) - 10:58, 11 August 2024
  • Thumbnail for Eptifibatide
    GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market. Eptifibatide...
    11 KB (947 words) - 16:29, 11 May 2024
  • Thumbnail for Monoclonal antibody
    Churchill Livingstone. pp. 241, for the examples infliximab, basiliximab, abciximab, daclizumab, palivusamab, gemtuzumab, alemtuzumab and rituximab, and mechanism...
    49 KB (4,964 words) - 09:59, 20 September 2024
  • Developed the drug that is recommended for all cardiac angioplasties (abciximab) 1974 Created the first MRI image of a living organism Discovered the...
    151 KB (13,767 words) - 11:45, 24 September 2024
  • points to the widely accepted pronunciation of any given INN. For example, abciximab is predictably /æbˈsɪksɪmæb/, because for INNs ending in -ciximab, the...
    26 KB (2,150 words) - 12:06, 11 September 2024
  • (INN) abatacept (USAN) Abasol (York Pharma) Abbokinase ABC Pack ABCD abciximab (INN) abecarnil (INN) Abecma abediterol (INN) Abegrin Abelcet (Sigma-Tau)...
    2 KB (210 words) - 19:12, 20 August 2024
  • Thumbnail for Fragment antigen-binding region
    form-factor for monoclonal antibodies designated for therapeutic use. The Fab abciximab, which inhibits blood clotting, works by disabling glycoprotein IIb/IIIa...
    6 KB (688 words) - 10:22, 9 September 2024
  • Thumbnail for Rockefeller University
    Sakmar was acting-president from 2002.) Barry Coller, who invented the Abciximab, currently serves as the Vice President for Medical Affairs. In all, as...
    37 KB (3,212 words) - 18:23, 27 June 2024
  • 1. ABACAVIR 2. ABCIXIMAB 3. ACAMPROSATE CALCIUM 4. ACEBUTOL HYDROCHLORIDE 5. ACLARUBICIN 6. ALBENDAZOLE 7. ALCLOMETASONE DIPROPIONATE 8. ACTILYSE 9. ACYCLOVIR...
    16 KB (253 words) - 16:47, 23 February 2023
  • adalumab (ada-li-u-mab). After 2017, it would be adalimab (ada-li-mab). Abciximab is a commonly used medication to prevent platelets from clumping together...
    38 KB (3,088 words) - 05:02, 8 August 2024
  • g. insulin and human growth hormone), antibodies (e.g. infliximab and abciximab) and vaccines; antibodies and enzymes used in diagnostics; industrial...
    5 KB (657 words) - 03:49, 15 May 2024
  • for plaque psoriasis in September 2006. Centocor also markets ReoPro (abciximab), a biologic agent indicated as an adjunct to coronary angioplasty (PTCA)...
    33 KB (3,157 words) - 23:31, 19 September 2024
  • physician known for his research in platelet physiology and for inventing the Abciximab. He is the David Rockefeller Professor, Physician-In-Chief, and Vice President...
    9 KB (749 words) - 18:17, 24 September 2023
  • Thumbnail for List of therapeutic monoclonal antibodies
    from the original on 15 July 2020. Retrieved 23 January 2020. "ReoPro Abciximab". DailyMed. 4 May 2020. Archived from the original on 6 September 2022...
    136 KB (4,020 words) - 06:13, 27 September 2024
  • stem. Examples of chimeric antibodies approved for human therapy include abciximab (ReoPro), basiliximab (Simulect), cetuximab (Erbitux), infliximab (Remicade)...
    14 KB (1,787 words) - 23:05, 9 January 2024
  • Drug Mechanism of action Indications Toxicity Abciximab A monoclonal antibody that binds to the glycoprotein receptor IIb/IIIa on activated platelets...
    20 KB (1,640 words) - 02:38, 30 March 2024
  • Thumbnail for Robert Wood Johnson I
    LifeScan Ortho Clinical Diagnostics Tasmanian Alkaloids Legacy brands Abciximab Actifed Axert Bactidol Bapineuzumab Benecol (US license) Benylin Caladryl...
    7 KB (764 words) - 16:32, 18 September 2024
  • Thumbnail for Platelet
    Ticagrelor Ticlopidine Desmopressin Factor VIIa Thrombopoietin mimetics Abciximab Eptifibatide Tirofiban Others: oprelvekin, romiplostim, eltrombopag, argatroban...
    71 KB (8,533 words) - 02:57, 18 September 2024
  • the efficacy of several angioplasty approaches, including tirofiban and abciximab infusion, as well as the implantation of both Sirolimus-Eluting and uncoated...
    27 KB (2,986 words) - 21:09, 28 February 2024
  • (INN) renytoline (INN) renzapride (INN) ReoPro (Eli Lilly). Redirects to abciximab. repagermanium (INN) repaglinide (INN) Repan reparixin (USAN) Repatha...
    6 KB (334 words) - 04:37, 2 July 2024
  • calcium B01AC09 Epoprostenol B01AC10 Indobufen B01AC11 Iloprost B01AC13 Abciximab B01AC15 Aloxiprin B01AC16 Eptifibatide B01AC17 Tirofiban B01AC18 Triflusal...
    3 KB (346 words) - 19:19, 12 March 2024
  • Thumbnail for Monoclonal antibody therapy
    date Route Type Target Indication (Targeted disease) BLA STN Drug Label abciximab ReoPro Centocor 12/22/1994 intravenous chimeric Fab GPIIb/IIIa Percutaneous...
    57 KB (4,072 words) - 11:12, 5 August 2024
  • Thumbnail for Renaissance School of Medicine at Stony Brook University
    by Jorge Benach Drugs that were developed by faculty of RSOM include: Abciximab (for cardiac angioplasty) by Barry S. Coller Doxycycline (for periodontal...
    19 KB (1,974 words) - 18:00, 11 May 2024
  • non-dihydropyridines diltiazem verapamil Eplerenone Finerenone Spironolactone Abciximab Aspirin Cangrelor Clopidogrel Eptifibatide Prasugrel Ticagrelor Tirofiban...
    5 KB (345 words) - 07:24, 2 July 2024
  • Thumbnail for Reperfusion therapy
    (2003). "Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to...
    30 KB (3,470 words) - 03:58, 25 December 2023
  • Metzler H, Rehak P, März W, Halwachs-Baumann G. Different effects of abciximab and cytochalasin D on clot strength in thrombelastography. J Thromb Haemost...
    19 KB (2,428 words) - 07:42, 19 May 2024
  • Thumbnail for Management of acute coronary syndrome
    patients undergoing percutaneous coronary intervention, consisting of abciximab, eptifibatide and tirofiban. Patients presenting with ST elevation that...
    54 KB (5,225 words) - 10:48, 21 July 2024